Pharmacokinetics and immunologic consequences of repeated administrations of purified heterologous and homologous butyrylcholinesterase in mice

Life Sciences

Volumn 85, Issue 17-18, 2009, Pages 657-661

  Sun, Wei ^a   Luo, Chunyuan ^a   Naik, Ramachandra S ^a   Doctor, Bhupendra P ^a   Saxena, Ashima ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Anti BChE antibodies; Bioscavenger; Human BChE; Mice; Mouse BChE; Pharmacokinetics

Indexed keywords

CHOLINESTERASE; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; REPEATED DRUG DOSE;

ANIMALS; BUTYRYLCHOLINESTERASE; FEMALE; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; SPECIES SPECIFICITY; TIME FACTORS;

MUS;

EID: 70349745701     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.09.005     Document Type: Article

References (23)

1. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Development Research 50 (2000) 298-308
2. Ashani Y., and Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicological Sciences 77 (2004) 358-367
3. Cascio C., Comite C., Ghira M., Lanza G., and Ponchione A. The use of serum cholinesterase in severe phosphorous poisoning. Personal experience. Minerva Anestesiologica 54 (1988) 337-338
4. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., and Gordon R.K. New approaches to medical protection against chemical warfare nerve agents (Chapter 6). In: Somani S.M., and Romano Jr. J.A. (Eds). Chemical Warfare Agents: Toxicity at Low Levels (2001), CRC Press, New York 191-214
5. Dutton R.W., and Swain S.L. Regulation of the immune response T-cell interactions. CRC Critical Reviews in Immunology 3 3 (1982) 209-261
6. Ellman G.L., Courtney K.D., Andres V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 7 (1961) 88-95
7. Garry P.J., Prince L.C., and Notari R.E. Half-life of human serum cholinesterase following blood transfusion. Research Communications in Chemical Pathology and Pharmacology 8 (1974) 371-380
8. Genovese R.F., Lu X.-C., Gentry M.K., Larrison R., and Doctor B.P. Evaluation of purified horse serum butyrylcholinesterase in rats. Proceedings of the Medical Defense Bioscience Review 31 (1993) 1035-1042
9. Gentry M.K., Nuwayser E.S., and Doctor B.P. Effects of repeated administration of butyrylcholinesterase on antibody induction in rabbits. Proceedings of the Medical Defense Bioscience Review 3 (1993) 1051-1056
10. Gentry M.K., Nuwayser E.S., and Doctor B.P. Immunological effect of repeated administration of cholinesterases in rabbits. Proceedings of the Medical Defense Bioscience Review 1 (1996) 183-191
11. George K.M., Montgomery M.A., Sandoval L.E., and Thompson C.M. Examination of cross-antigenicity of acetylcholinesterase and butyrylcholinesterase using anti-acetylcholinesterase antibodies. Toxicology Letters 126 2 (2002) 99-105
12. Guven M., Sungur M., Eser B., Sari I., and Altuntas F. The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning. Journal of Toxicology. Clinical Toxicology 42 5 (2004) 617-623
13. Jenkins T., Balinsky D., and Patient D.W. Cholinesterase in plasma: first reported absence in the Bantu: half-life determination. Science 156 3783 (1967) 1748-1750
14. Laub P.B., and Gallo J.M.J. NCOMP-a Windows-based computer program for noncompartmental analysis of pharmacokinetic data. Journal of Pharmaceutical Sciences 85 (1996) 393-395
15. Matzke S.M., Oubre J.L., Caranto G.R., Gentry M.K., and Galbicka G. Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys. Pharmacology, Biochemistry and Behavior 62 3 (1999) 523-530
16. Maxwell D.M., Castro C.A., De La Hoz D.M., Gentry M.K., Gold M.B., Solana R.P., Wolfe A.D., and Doctor B.P. Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicology and Applied Pharmacology 115 1 (1992) 44-49
17. Ostergaard D., Viby-Mogensen J., Hanel H.K., and Skovgaard L.T. Half-life of plasma cholinesterase. Acta Anaesthesiologica Scandinavica 32 3 (1988) 266-269
18. Raveh L., Grauer E., Grunwald J., Cohen E., and Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicology and Applied Pharmacology 145 (1997) 43-53
19. Rosenberg Y., Luo C., Ashani Y., Doctor B.P., Fischer R., Wolfe G., and Saxena A. Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyryl-cholinesterase. Life Sciences 72 (2002) 125-134
20. Saxena A., Sun W., Luo C., and Doctor B.P. Human serum butyrylcholinesterase: In vitro and in vivo stability, pharmacokinetics, and safety in mice. Chemico-Biological Interactions 157-158 (2005) 199-203
21. Saxena A., Luo C., and Doctor B.P. Developing procedures for the large-scale purification of human serum butyrylcholinesterase. Protein Expression and Purification 61 (2008) 191-196
22. Stovner J., and Stadskleiv K. Suxamethonium apnoea terminated with commercial serum cholinesterase. Acta Anaesthesiologica Scandinavica 20 3 (1976) 211-215
23. UniProt Consortium. The universal protein resource. Nucleic Acids Research 37 (2009) D169-D174